Vanadyl sulfate treatment improves oxidative stress and increases serum paraoxonase activity in streptozotocin-induced diabetic rats


Tas S., Sarandol E., Ziyanok-Ayvalik S., Ocak N., Serdar Z., Dirican M.

NUTRITION RESEARCH, vol.26, no.12, pp.670-676, 2006 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 12
  • Publication Date: 2006
  • Doi Number: 10.1016/j.nutres.2006.09.022
  • Journal Name: NUTRITION RESEARCH
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.670-676
  • Keywords: diabetes, oxidative stress, vanadyl sulfate, paraoxonase, streptozotocin, ANTIOXIDANT STATUS, AUTOXIDATIVE GLYCOSYLATION, GLUCOSE AUTOXIDATION, LIPID-PEROXIDATION, IN-VIVO, MELLITUS, PLASMA, LDL, SUSCEPTIBILITY, AMINOGUANIDINE

Abstract

Vanadyl sulfate (VS) may reduce oxidative stress related to its hypoglycemic and hypolipidemic effects in diabetes mellitus; besides, as a catalytic element, it may induce lipid peroxidation. Studies investigating effects of VS on the oxidative-antioxidative systems in diabetes yielded conflicting results, and this study was designed to investigate the effects of VS on the oxidative-antioxidative systems in streptozotocin-induced (65 mg/kg) diabetic rats. Vanadyl sulfate was administered in drinking water 0.75 mg/mL during 5 weeks after the induction of diabetes. Thirty-two male Wistar rats were randomly divided into four groups: control (C), control + vanadyl sulfate (C + VS), diabetes (D), and diabetes + vanadyl sulfate (D + VS). Vanadyl sulfate reduced the enhanced glucose, lipid, and tissue malondialdehyde levels and increased the reduced serum paraoxonase and arylesterase activity in the D + VS group. Plasma malondialdehyde level was significantly increased in the C + VS group, compared with the control group. Erythrocyte glutathione peroxidase activity was significantly higher in the C + VS and D + VS groups, compared with the C and the D groups, respectively.The results of the present study suggest that (i) VS has antioxidative potential in streptozotocin-treated rats, and it might be used as a supportive therapeutic agent in uncontrolled diabetes; (ii) VS treatment might play a role in the improvement of serum paraoxonase activity and, thus, inhibit the progression of atherosclerosis; (iii) the prooxidant potential of the VS should be taken into account. (c) 2006 Elsevier Inc. All rights reserved.